Matthew L. Posard - 10 Jun 2022 Form 4 Insider Report for Talis Biomedical Corp

Role
Director
Signature
/s/ J. Roger Moody, Jr., Attorney-in-Fact for Matthew L. Posard
Issuer symbol
TLIS on OTC
Transactions as of
10 Jun 2022
Net transactions value
$0
Form type
4
Filing time
13 Jun 2022, 17:41:05 UTC
Previous filing
31 May 2022
Next filing
16 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLIS Stock Option (right to buy) Award $0 +95,000 $0.000000 95,000 10 Jun 2022 Common Stock 95,000 $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.